2026 Executive Playbook: AI Strategies for Post-Acute Leaders On-Demand Webinar Series-AI in Post-Acute Care: Separating Value from Risk

Video Transcription

Video Summary

The webinar discussed how post-acute care organizations should evaluate clinical AI through regulatory, clinical, and financial lenses. Allison Rainedy and Paul Minton emphasized that AI adoption is growing faster than regulation, leaving providers responsible for internal oversight, validation, and accountability because federal guidance is light and state rules are fragmented.<br /><br />They explained that AI risk in healthcare ranges from high-risk tools that directly drive clinical decisions to moderate-risk tools that support, but do not replace, nursing judgment. Key dangers include privacy breaches, hallucinations, bias, drift, unsafe workarounds, and poor workflow fit. Leaders were urged to start with a defined pain point, choose narrowly scoped tools, and require evidence of safety, bias monitoring, escalation/rollback plans, and population fit.<br /><br />Paul highlighted that tools should be classified at intake: transparent “glass box” advisory tools may avoid FDA device oversight, while opaque or directive tools may require formal review. He also warned about unauthorized “shadow AI,” noting real-world staff use of unapproved tools due to workflow pressure. The session closed with a governance framework centered on continuous monitoring, measurable outcomes, and matching safeguards to the level of risk.

Keywords

clinical AI

post-acute care

regulatory oversight

AI risk management

bias monitoring

workflow fit

governance framework